Showing papers by "Jaume Reventós published in 1995"
TL;DR: Few reports suggest that c‐erbB‐2/neu, which is a prognostic marker in breast cancer, epidermal growth factor receptor (EGFR), and fibroblast growth factor‐3 (FGF‐3/INT‐2), which has been found to be amplified in breast and ovarian cancer, could be implicated in the development of endometrial adenocarcinoma.
Abstract: Background. It currently is well established that the activation of protooncogenes could trigger uncontrolled cell growth and cancer development. Although this correlation already has been evidenced in several human tumors, no conclusive studies have related oncogene activation with the development of endometrial neoplasia. Nevertheless, few reports suggest that c-erbB-2/neu, which is a prognostic marker in breast cancer, epidermal growth factor receptor (EGFR), which is overexpressed in a variety of neoplasms, and fibroblast growth factor-3 (FGF-3/INT-2), which has been found to be amplified in breast and ovarian cancer, could be implicated in the development of endometrial adenocarcinoma. Methods. Amplification of c-erbB-2/neu, EGFR, and FGF-3/INT-2 was examined in 50 endometrial carcinomas, 10 adenomatous hyperplasias, and 50 normal endometrial samples, using the genomic differential polymerase chain reaction with the single copy reference gene interferon-gamma. Quantitation of the ratios between the amplified bands was assessed by image analysis. Results. c-erbB-2 and FGF-3/INT-2 were amplified in a first group of 7 (14%) and a further group of 7 (14%) patients, respectively, of a total of 50 in whom endometrial cancer had been studied. In the latter seven, a strong correlation between this genetic marker and an advanced disease stage (International Federation of Gynecology and Obstetrics Stage III) was found. In two patients, both genes were amplified. No EGFR gene amplification was detected in any case. Conclusion. c-erbB-2/neu but not EGFR gene amplification was detected and FGF-3/INT-2 amplification and advanced disease were correlated in endometrial cancer. Cancer 1995 ; 75 :2139-46.
23 citations
TL;DR: High rate of MDR‐I expression without gene amplification was detected in all endometrial‐carcinoma samples, as well as in 10 adenomatous hyperplasias and 50 samples of normal endometrium, and MRP appeared to be expressed at moderate levels in normalendometrial tissue.
Abstract: The present study was undertaken to determine the pattern of expression of 2 molecular markers of multidrug resistance, the MDR-1 and MRP genes, in endometrial carcinomas from 50 untreated patients using a PCR semi-quantitative assay. In addition, PCR analysis of MDR-1 and MRP gene amplification was obtained in each case. High rate of MDR-1 expression without gene amplification was detected in all endometrial-carcinoma samples, as well as in 10 adenomatous hyperplasias and 50 samples of normal endometrium. On the other hand, MRP appeared to be expressed at moderate levels in normal endometrial tissue, while relatively high levels of MRP expression without gene amplification were occasionally observed in endometrial-carcinoma samples.
18 citations